Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
Do you consider steroid-sparing agents for treatment of patients with steroid responsive relapsed Hashimoto Encephalopathy?
Related Questions
How do you approach the "wearing off" phenomenon for patients with multiple sclerosis on B-cell-depleting therapies?
Are there any precautions that should be taken when transitioning a patient with multiple sclerosis from one disease modifying therapy to another?
How frequently do you recommend ordering labs to monitor for side effects of disease-modifying therapies for multiple sclerosis?
Do you treat tumefactive multiple sclerosis differently than other forms of MS both in the acute and maintenance phase?
How would you approach the decision to escalate DMT in a patient with relapsing multiple sclerosis who has two to three new T2 lesion but no clinical symptoms?
How do you decide on initial and sequential anti-CD20 therapy for patients with multiple sclerosis given the availability of rituximab, ocrelizumab, ublituximab, and ofatumumab?
What is your approach to immune management in opsoclonus-myoclonus-ataxia syndrome?
What baseline visual testing, if any, do you recommend at diagnosis for patients with multiple sclerosis who deny visual complaints?
What is your treatment approach to neurological Sjogrens disease with both peripheral neuropathy and transverse myelitis?
What is the diagnostic approach and management for suspected Hashimoto Encephalitis?
